China Universal Asset Management Co. Ltd. Has $290,000 Stock Holdings in Zai Lab Limited (NASDAQ:ZLAB)

China Universal Asset Management Co. Ltd. grew its position in Zai Lab Limited (NASDAQ:ZLAB) by 15.7% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 11,061 shares of the company’s stock after buying an additional 1,502 shares during the period. China Universal Asset Management Co. Ltd.’s holdings in Zai Lab were worth $290,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in ZLAB. Y Intercept Hong Kong Ltd acquired a new stake in Zai Lab in the third quarter worth about $225,000. Daiwa Securities Group Inc. boosted its stake in Zai Lab by 4,851.8% in the third quarter. Daiwa Securities Group Inc. now owns 9,557 shares of the company’s stock valued at $231,000 after acquiring an additional 9,364 shares during the last quarter. RBF Capital LLC acquired a new stake in Zai Lab during the 3rd quarter worth $241,000. Dimensional Fund Advisors LP bought a new stake in shares of Zai Lab during the 2nd quarter valued at $270,000. Finally, Point72 Asset Management L.P. acquired a new position in shares of Zai Lab in the 3rd quarter valued at $325,000. Institutional investors own 41.65% of the company’s stock.

Analysts Set New Price Targets

ZLAB has been the subject of a number of analyst reports. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Zai Lab in a research note on Friday, October 25th. JPMorgan Chase & Co. boosted their target price on Zai Lab from $38.00 to $44.00 and gave the stock an “overweight” rating in a research report on Monday, October 21st.

Insider Buying and Selling

In other Zai Lab news, insider Rafael Amado sold 7,583 shares of Zai Lab stock in a transaction that occurred on Tuesday, December 31st. The shares were sold at an average price of $26.28, for a total value of $199,281.24. Following the transaction, the insider now owns 33,834 shares of the company’s stock, valued at approximately $889,157.52. The trade was a 18.31 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 13.88% of the stock is currently owned by company insiders.

Zai Lab Stock Down 2.3 %

Shares of NASDAQ ZLAB opened at $27.19 on Monday. Zai Lab Limited has a twelve month low of $13.48 and a twelve month high of $36.60. The company’s fifty day moving average is $26.67 and its 200-day moving average is $24.25. The stock has a market cap of $2.98 billion, a price-to-earnings ratio of -9.82 and a beta of 1.00.

Zai Lab Profile

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.